Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Evaluation of the CDC Molecular Detection of Drug Resistance Testing Service for Isolates of *Mycobacterium tuberculosis* Complex

Please help us to continue improving our MDDR testing service by answering a few simple questions.

How did you <u>first</u> get information on the MDDR testing service offered by CDC?

- ○ *CDC website*
- ○ *"Dear Colleague" letter*
- ○ *Conference call with CDC*
- ○ *Professional meeting*
- ○ *Regional Training and Medical Consultation Center (RTMCC)*
- ○ *TB control program*
- ○ *Another public health laboratory*
- ○ *CDC TB laboratory Consultant*

Who initiates requests for the molecular detection of drug resistance (MDDR) testing service at CDC? (Select all that apply.)

- ☐ *Health care provider*
- ☐ *TB control program*
- ☐ *Laboratory*
- ☐ *Laboratory only after consultation with program staff*

Other. Please explain

Were you satisfied with the turnaround time for receiving results from the MDDR testing service?

- ○ *Very satisfied*
- ○ *Satisfied*
- ○ *Neither satisfied nor dissatisfied*
- ○ *Dissatisfied*
- ○ *Very dissatisfied*

What is the usual time frame for your laboratory to report interim molecular results from the MDDR testing service to health care providers?

- ○ *Molecular results are reported directly to health care provider within 1 business day of receipt from CDC*
- ○ *Molecular results are reported directly to health care provider within 2 business days of receipt from CDC*
- ○ *Reporting time to health care provider varies depending on circumstances*
- ○ *Molecular results are reported to health care provider by TB Control Program*
- ○ *Not applicable. Health care provider receives separate MDDR report from CDC*

In general, does your laboratory withhold reporting molecular results from the MDDR service until conventional testing is completed by CDC?

- *Yes*
- *Sometimes*
- *No, molecular results are reported as soon as possible*
- *Not applicable. Molecular results are reported to health care provider by TB Control Program*
- *Not applicable. Health care provider receives separate report from CDC*

Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Information Collection Review Office, 1600 Clifton Road NE, MS D- 74, Atlanta, Georgia 30333; ATTN: PRA (0920-0879).

Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Please state why molecular results are withheld.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Please state why molecular results are sometimes withheld.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

In general, does your laboratory withhold reporting molecular results from the CDC MDDR service until conventional drug susceptibility testing is completed by your laboratory?

- *Yes*
- *Sometimes*
- *No, molecular results are reported as soon as possible*
- *Not applicable. Molecular results are reported to health care provider by TB Control Program*
- *Not applicable. Health care provider receives separate report from CDC*

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Please state why the molecular results are withheld.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Please state why the molecular results are sometimes withheld.

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

How are results from the CDC MDDR service reported? (Select all that apply)

- [ ] *Verbally*
- [ ] *Copy of CDC report is provided*
- [ ] *CDC results are transcribed into LIMS for reporting*
- [ ] *Not applicable. CDC results are not reported by our laboratory*

Does your laboratory compare molecular results from the CDC MDDR service with your local test results for conventional drug susceptibility with first-line drugs?

- ( ) *Yes, we always compare molecular results from CDC with our local test results*
- ( ) *Sometimes we compare molecular results from CDC with our local test results*
- ( ) *No, we report the molecular results from CDC without comparing to our local test results*
- ( ) *Not applicable. We do not perform first-line drug susceptibility testing*

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Why do you compare molecular results from CDC with your local testing results for first-line drugs?(Select all that apply)

- ☐ *Results are compared for quality assurance purposes*
- ☐ *Results are compare for increasing understanding of molecular testing*
- ☐ *Results are compared to find discordance*
- ☐ *Results are compared in preparation for consultation with the health care provider of TB Control Program if needed*
- ☐ *Other*

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Why do you not compare molecular results from CDC with local testing? (Select all that apply)

- ☐ *Our laboratory is not fully qualified to compare results from CDC with our local results*
- ☐ *We report molecular results from CDC and results from local testing without further comparison and interpretation*
- ☐ *We only compare conventional drug susceptibility results from CDC with our local testing*
- ☐ *Other*

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Do you compare molecular results from the CDC for potential discordance with second-line drug susceptibility test results obtained from local testing?

- ○ *Yes, always*
- ○ *Yes, sometimes*
- ○ *No, we do not perform conventional second-line drug susceptibility testing*
- ○ *No, we perform conventional second-line drug susceptibility testing but do not compare with molecular results from CDC*

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Please explain why you sometimes compare molecular results from the CDC for potential discordance with second-line drug susceptibility test results obtained from local testing.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

If the molecular results from the MDDR service are the first results available regarding susceptibility of an isolate, how do these results impact conventional drug susceptibility testing performed locally?

- *Results have no impact on local testing*
- *Local results are disregarded*
- *If resistance is indicated by molecular results, isolate is referred to another laboratory other than CDC for additional testing*
- *Other*

Please explain how the molecular results from MDDR service impact testing performed locally.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Have you observed, as indicated on the CDC final report, potential discordance between the preliminary molecular results and the phenotypic test results reported by CDC? (In answering this question, only consider results from CDC and not local testing)

- ○ *Yes, we have observed discordance*
- ○ *No, we have not observed discordance*
- ○ *No, we do not examine CDC results for discordance*

Powered by snap Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

What additional actions did you take when you observed potential discordance between the preliminary molecular results and the phenotypic test results reported by CDC? (Select all that apply)

- ☐ *No additional actions were taken*
- ☐ *Contacted the Division of Tuberculosis Laboratory Branch at CDC to discuss results*
- ☐ *Retested isolate in our laboratory*
- ☐ *Withheld sending CDC results to health care provider or TB Control*
- ☐ *Contacted TB Control Program to notify them of potential discordance*
- ☐ *Referred an isolate from the patient to another laboratory other than CDC for molecular testing*
- ☐ *Referred an isolate from the patient to another laboratory other than CDC for conventional drug susceptibility testing*
- ☐ *Additional action taken by our laboratory depends on what drug is indicated as having the potential discordance (i.e., contact CDC about the potential discordant results for rifampin but not for isoniazid)*

Please provide any additional information regarding actions taken.

Back Reset Next

Form Approved
OMB No. 0920-0879
Expiration Date 03/31/2014

Did you have difficulty interpreting the molecular results from the MDDR service as provided on the report form?

- *The results were very difficult to interpret*
- *The results were somewhat difficult to interpret*
- *The results were not difficult to interpret*
- *The results were very easy to interpret*

Were you comfortable discussing interpretation of the molecular results from the MDDR service with health care providers or TB Control?

- *Very comfortable discussing the results*
- *Had some difficulty explaining the results*
- *In most instances, not contacted for help interpreting the results*

If you experienced any difficulty interpreting the results from the MDDR service, where did you seek help? (Select all that apply)

- [ ] *Contacted CDC TB Laboratory for help interpreting the report*
- [ ] *Visited the CDC website for more information on the MDDR testing service*
- [ ] *Consulted with clinician for help in interpreting results*
- [ ] *Did my own research to find information on interpretation*
- [ ] *Contacted local TB Program in consultation for interpreting the results*
- [ ] *Contacted RTMCC in consultation for interpreting the results*
- [ ] *I did not seek help for interpreting the results*

Back Reset Submit